Stifel Downgrades Kalvista Pharmaceuticals Inc (KALV) to Hold on Proposed Acquisition
Tweet
Share
E-mailGet Alerts KALV Hot Sheet
Price: $27.00 --0%
Rating Summary:
7 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 27
Rating Summary:
7 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 27
Join SI Premium – FREE
Stifel analyst Paul Matteis downgraded Kalvista Pharmaceuticals Inc (NASDAQ: KALV) from Buy to Hold with a price target of $27.00 (from $42.00).
For an analyst ratings summary and ratings history on Kalvista Pharmaceuticals Inc click here. For more ratings news on Kalvista Pharmaceuticals Inc click here.
Shares of Kalvista Pharmaceuticals Inc closed at $26.72 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 22nd Century Group files prospectus for warrant share resale
- Super League Enterprise (SLE) files for 1.07M share offering by selling stockholders
- Battery X Metals adds auto industry advisor to board
Create E-mail Alert Related Categories
DowngradesRelated Entities
Stifel, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
